UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
Quarterly Report Under Section 13 or 15(d) of
The Securities Exchange Act of 1934
For quarter ended: March 31, 1997 Commission File No. 1-12575
UTAH MEDICAL PRODUCTS, INC.
(Exact name of Registrant as specified in its charter)
UTAH 87-0342734
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
7043 South 300 West
Midvale, Utah 84047
Address of principal executive offices
Registrant's telephone number: (801) 566-1200
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Sections 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports) and; (2) has been subject to such
filing requirements for the past 90 days. Yes X No
The number of shares outstanding of the registrant's common stock as of May
13, 1997: 8,488,786
<PAGE>
- -------------------------------------------------------------------------------
PART I. FINANCIAL INFORMATION
- -------------------------------------------------------------------------------
ITEM 1. FINANCIAL STATEMENTS
UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARY
BALANCE SHEETS AS OF MARCH 31, 1997
AND DECEMBER 31, 1996
(Unaudited)
MARCH 31, DECEMBER 31,
1997 1996
------------ -----------
ASSETS
Cash $1,904,590 $3,038,956
Investments 1,069,975 1,458,543
Accounts receivable - net 2,600,767 3,804,857
Other receivables 1,224,725 1,205,985
Inventories 5,928,591 4,750,442
Prepaid expenses 248,976 91,273
Deferred income taxes 603,875 595,639
----------- -----------
Total current assets 13,581,499 14,945,695
PROPERTY AND EQUIPMENT - NET 13,298,868 13,367,597
INTANGIBLE ASSETS - NET 803,351 602,393
----------- -----------
TOTAL $27,683,718 $28,915,685
LIABILITIES AND STOCKHOLDERS' EQUITY =========== ===========
CURRENT LIABILITIES:
Accounts payable $1,974,510 $1,885,743
Accrued expenses:
Payroll and payroll taxes 702,851 1,132,309
Reserve for litigation expense 704,790 649,840
Income taxes payable 329,193
Other 331,182 271,947
Deferred revenue 110,600 135,600
----------- -----------
Total current liabilities 4,153,126 4,075,439
DEFERRED REVENUE 66,063 87,492
DEFERRED INCOME TAXES 463,949 369,759
----------- -----------
Total liabilities 4,683,138 4,532,690
----------- -----------
STOCKHOLDERS' EQUITY:
Preferred stock - $.01 par value;
authorized - 5,000,000 shares; no shares
issued or outstanding
Common stock - $.01 par value; authorized
- 50,000,000 shares; issued - March 31,
1997, 8,608,486 shares December 31,
1996, 8,785,736 shares 86,085 87,857
Unrealized gain on investments
available-for-sale, net of tax 71,124 58,494
Cumulative foreign currency translation
adjustment (96,902) 217,444
Retained earnings 22,940,273 24,019,200
----------- -----------
Total stockholders' equity 23,000,580 24,382,995
----------- -----------
TOTAL $27,683,718 $28,915,685
=========== ===========
see notes to consolidated financial statements
<PAGE>
UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARY
STATEMENTS OF OPERATIONS FOR THE THREE MONTHS
ENDED MARCH 31, 1997 AND MARCH 31, 1996
(Unaudited)
THREE MONTHS ENDED
MARCH 31
------------------------
1997 1996
---------- ----------
NET SALES $5,173,394 $9,967,590
COST OF SALES 2,465,794 5,372,531
---------- ----------
GROSS MARGIN 2,707,600 4,595,059
---------- ----------
EXPENSES:
Selling, general and administrative 1,377,138 1,448,347
Research & development 237,938 358,874
---------- ----------
Total 1,615,076 1,807,221
---------- ----------
INCOME FROM OPERATIONS 1,092,524 2,787,838
OTHER INCOME 528,401 1,098,758
---------- ----------
INCOME BEFORE INCOME TAX EXPENSE 1,620,925 3,886,596
INCOME TAX EXPENSE 580,940 1,403,061
---------- ----------
NET INCOME $1,039,985 $2,483,535
========== ==========
EARNINGS PER COMMON AND COMMON
EQUIVALENT SHARE $0.12 $0.25
========== ==========
EARNINGS PER COMMON SHARE ASSUMING
FULL DILUTION $0.12 $0.25
========== ==========
WEIGHTED AVERAGE NUMBER OF COMMON AND
COMMON EQUIVALENT SHARES 8,730,724 10,041,513
========== ==========
WEIGHTED AVERAGE NUMBER OF COMMON
SHARES ASSUMING FULL DILUTION 8,730,724 10,041,513
========== ==========
See notes to consolidated financial statements
<PAGE>
UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARY
STATEMENTS OF CASH FLOWS
FOR THE THREE MONTHS ENDED MARCH 31, 1997 AND MARCH 31, 1996
(Unaudited)
<TABLE>
<CAPTION>
MARCH 31,
1997 1996
---------- ----------
<S> <C> <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income $1,039,985 $2,483,535
---------- ----------
Adjustments to reconcile net income to net cash
provided by operating activities:
Depreciation and amortization 309,328 341,807
Provision for losses on accounts receivable 1,109 11,385
Loss on disposal of assets 7,221 372,311
Deferred income taxes 78,311 42,114
Tax benefit attributable to exercise and
disposition of incentive stock options and
stock purchase rights 14,877 56,383
Changes in operating assets and liabilities:
Accounts receivable - trade 1,202,981 923,641
Accrued interest and other receivables (18,739) 7,105
Inventories (1,178,150) (340,741)
Prepaid expenses (157,703) (14,966)
Accounts payable 88,767 (88,849)
Accrued expenses 13,920 1,059,928
Deferred revenue (46,429) (21,429)
---------- ----------
Total adjustments 315,493 2,348,689
---------- ----------
Net cash provided by operating activities 1,355,478 4,832,224
---------- ----------
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures for:
Property and equipment (520,520) (1,100,277)
Intangible assets (214,408) (250,240)
Purchases of investments (112,200) (2,232,923)
Proceeds from sale and maturities of investments 516,977 3,035,000
Proceeds from sale of property and equipment 3,500 8,250
---------- ----------
Net cash used in investing activities (326,651) (540,190)
---------- ----------
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock 95,173 160,063
Common stock purchased and retired (2,258,366) (1,118,623)
---------- ----------
Net cash used in financing activities (2,163,193) (958,560)
---------- ----------
NET INCREASE (DECREASE) IN CASH (1,134,366) 3,333,474
CASH AT BEGINNING OF PERIOD 3,038,956 5,064,913
---------- ----------
CASH AT END OF PERIOD $1,904,590 $8,398,387
========== ==========
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid during the period for income taxes
$12,260 $182,245
See notes to consolidated financial statements
<PAGE>
UTAH MEDICAL PRODUCTS, INC.
NOTES TO FINANCIAL STATEMENTS
(unaudited)
(1) The unaudited financial statements presented herein have been prepared in
accordance with the instructions to form 10-Q and do not include all of the
information and note disclosures required by generally accepted accounting
principles. These statements should be read in conjunction with the financial
statements and notes thereto included in the Utah Medical Products, Inc. ("UM"
or "the Company") annual report on form 10-K for the year ended December 31,
1996. The accompanying financial statements have not been examined by
independent accountants in accordance with generally accepted auditing
standards, but in the opinion of management such financial statements include
all adjustments (consisting only of normal recurring adjustments) necessary to
summarize fairly the Company's financial position and results of operations.
The results of operations for the three months ended March 31, 1997 may not be
indicative of the results that may be expected for the year ending December 31,
1997.
(2) Inventories at March 31, 1997 and December 31, 1996 consisted of the
following:
March 31, December 31,
1997 1996
---------- ----------
Finished goods $1,258,403 $1,000,438
Work-in-process 1,360,736 1,010,086
Raw materials 3,309,452 2,739,918
---------- ----------
Total $5,928,591 $4,750,442
(3) The Company has adopted the disclosure-only provisions of Statement of
Financial Accounting Standards (SFAS) No. 123, "Accounting for Stock-Based
Compensation." Accordingly, no compensation cost has been recognized in the
financial statements.
(4) In February 1997, the Financial Accounting Standards Board issued SFAS No.
128, "Earnings per Share." This standard establishes standards for computing
earnings per share ("EPS"). SFAS No. 128 simplifies the approach for computing
EPS previously found in APB Opinion No. 15. It replaces the presentation of
primary EPS with a presentation of basic EPS. It also requires dual
presentation of basic and diluted EPS on the face of the income statement for
all entities with complex capital structures. SFAS No. 128 is effective for
financial statements issued for periods ending after December 15, 1997,
including interim periods. Early adoption is not permitted. The computation of
basic and diluted EPS under SFAS No. 128 would not have changed the net income
amounts for the three months ended March 31, 1997 and 1996 herein reported.
(5) Forward-Looking Information. This report contains certain forward-
looking statements and information relating to the Company that are based on the
beliefs of management as well as assumptions made by, and information currently
available to, management. When used in this document, the words "anticipate,"
"believe," "should," "project," "estimate," "expect," "intend" and similar
expressions, as they relate to the Company or its management, are intended to
identify forward-looking statements. Such statements reflect the current view
of the Company respecting future events and are subject to certain risks,
uncertainties, and assumptions, including the risks and uncertainties noted
throughout the document. Although the Company has attempted to identify
important factors that could cause the actual results to differ materially,
there may be other factors that cause the forward statement not to come true as
anticipated, believed, projected, expected, or intended. Should one or more of
these risks or uncertainties materialize, or should underlying assumptions prove
incorrect, actual results may differ materially from those described herein as
anticipated, believed, projected, estimated, expected, or intended.
General risk factors that may impact the Company's revenues include the
market acceptance of competitive products, obsolescence caused by new
technologies, the possible introduction by competitors of new products that
claim to have many of the advantages of UM's products at lower prices, the
timing and market acceptance of UM's own new product introductions, UM's ability
to efficiently manufacture its products, including the reliability of suppliers,
success in gaining access to important global distribution channels, marketing
success of UM's distribution and sales partners, budgetary constraints, the
timing of regulatory approvals for newly introduced products, and third party
reimbursement.
Risk factors, in addition to the risks outlined in the previous paragraph
that may impact the Company's assets and liabilities, as well as cash flows,
include risks inherent to companies manufacturing products used in health care
including claims resulting from the improper use of devices and other product
liability claims, defense of the Company's intellectual property, productive use
of assets in generating revenues, management of working capital including
inventory levels required to meet delivery commitments at a minimum cost, and
timely collection of accounts receivable.
Additional risk factors that may affect non-operating income include the
continuing viability of the Company's technology license agreements, actual cash
and investment balances, asset dispositions, and acquisition activities that may
require external funding.
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
Results of Operations
Because of the relatively short span of time, results for any given three
month period in comparison with a previous three month period may not be
indicative of comparative results for the year as a whole.
a) Overview
First quarter (1Q) 1997 financial results were disappointing compared to 1Q
1996, which was the Company's record for quarterly earnings per share. Sales
suffered in comparison because of the permanent decline in sales of disposable
pressure transducers to Baxter, the transient pipeline "unfilling" from changing
two regional independent distributors to direct sales representatives, and
increased competition from two manufacturers which UM believes are infringing
its patents. Despite sales which declined by 48%, gross profit margins improved
to 52.3% of sales as compared to 46.1% of sales in 1Q 1996. Operating profit
margins were hampered because of the lower sales volume, which caused operating
expenses to increase from 18% of sales in 1Q 1996 to 31% of sales in 1Q 1997,
despite the fact that actual operating expenses in 1Q 1997 were about $200,000
lower than in 1Q 1996. 1Q 1997 income before taxes declined disproportionately
because non-operating income received from other medical companies for the use
of UM's technology was unusually high in the prior year's first quarter (about
$570,000 higher in 1Q 1996 than in 1Q 1997).
b) Revenues
UM divides revenues into three product-line categories: 1) critical care,
which is comprised primarily of components used in invasive blood pressure
monitoring, but also includes components for other types of pressure
monitoring, as well as disposable respiratory products used in hospitals; 2)
obstetrics, which is comprised mainly of devices for monitoring intrauterine
pressure during labor and delivery, although to a lesser extent electrodes for
fetal heart rate monitoring as well as other labor and delivery supplies, and a
product which unifies and improves clinician safety in the multiple step
procedure of clamping, cutting, and drawing blood samples from the umbilical
cord immediately following childbirth; and 3) gynecology, which comprises an
electrosurgery system used in a procedure called LETZ(R), tools used in other
minimally invasive surgical procedures including diagnostic laparoscopies, and a
device for the conservative treatment of urinary incontinence.
Critical care product revenues were $2,042,000 (39% of total revenue) in 1Q
1997, compared to $5,790,000 (58% of total revenue) in 1Q 1996. Sales to Baxter
in 1Q 1997 were $454,000 compared to $3,794,000 in 1Q 1996. As previously
announced, Baxter stopped purchasing disposable pressure transducers ("DPT")
from UM at the end of 1996. 1Q 1997 Baxter sales were miscellaneous components.
First quarter 1997 sales to Vital Signs, Inc., (anticipated as a replacement
distributor for Baxter) were virtually zero. UM is actively seeking other
potential DPT distribution partners in the U.S. needed to exploit the Company's
DPT manufacturing capabilities.
In the U.S., critical care blood pressure monitoring is a mature business
dominated by two large suppliers, Baxter and Abbott. UM's non-Baxter critical
care sales were $1,588,000 in 1Q 1997 compared to $1,996,000 in 1Q 1996, a 20%
decline. The decline is expected to be temporary. Non-Baxter critical care
sales are expected to return to the 1996 quarterly average of about $2,000,000
per quarter for the remainder of 1997.
The obstetrics revenue category declined 32.2% in 1Q 1997 from the same
quarter of 1996 and represented 45% of total sales compared to 35% in 1996.
Sales of obstetrics products in 1Q 1997 were $2,335,000 compared to $3,445,000
in 1Q 1996. At the beginning of 1997, UM continued to convert from distributors
to direct sales representatives for geographical territories that represented
about 25% of UM's domestic business. Although the most recent changes are
expected to have a positive impact on sales later in the year, 1Q sales suffered
as terminated distributors were allowed to deplete their inventories. UM has
been converting its Ob/Gyn sales resources in the U.S. from third party
distributors to its own employed direct representatives for the last five years.
Additionally, two companies are now competing with UM for its Intran(R)
business with cheaper products. Because the Company believes both are
infringing UM patents, legal remedies are being sought against those companies.
In addition, UM has retained an independent marketing firm to help focus the
Company's efforts to provide evidence needed to the marketplace to support the
value of Intran compared with competing products.
The third product line, gynecology products, includes Liberty(R), a system
for conservatively treating urinary incontinence, Lumin(R), a unique tool used
in laparoscopic procedures to manipulate the uterus, and EpitomeO, a unique
ceramic scalpel, in addition to UM's LETZ system of electrosurgery equipment and
disposable electrodes. Gynecology revenues increased 9% to $797,000 in 1Q 1997
from $732,000 in 1Q 1996, and represented 15% of total revenues. Epitome unit
sales increased to 7,500 units in 1Q 1997 from about 6,500 units in 4Q 1996. UM
continues to seek a substantial OEM marketing partner who has the ability to
spur Epitome sales in non-gynecology surgical specialties. UM's past successes
with its gynecology products resulted from providing physician training along
with equipment and tools designed for specific procedures. The Company believes
that future success will depend on similar efforts. Effective marketing of new
products launched in the past year represent significant challenges for UM's
marketing resources. Recently, UM announced an agreement with the Urological
Division of C.R. Bard, Inc. to conduct a pilot sales program to test the
distribution capability of UM's direct sales representatives who call on office
gynecology practices in selling the Bard 4 Channel Fiberoptic Urodynamic System.
Despite the difficult time UM is now having in sales activity, long term
prospects remain bright. The Company has in place a number of programs and
actions that should change the current situation summarized as follows: 1) new
products with patent protection that address unfilled needs with large market
potential, 2) continuing discovery and investment with leading practitioners in
improving cost-effective care and patient outcomes in specific disease
categories, 3) globalization of business, 4) continual reduction in costs of
manufacturing, 5) aggressive litigation regarding protection of proprietary
rights, 6) an architectural shift in marketing programs designed to focus on
customers' key needs and prove the unique value of our products, and 7) active
deal-making initiatives to expand distribution partners for existing products
and expand availability of marketable products to our existing distribution
resources.
First quarter 1997 foreign sales were $1,194,000 (23% of total sales)
compared to $2,750,000 (28% of total sales) in 1Q 1996. Lower sales to Baxter
accounted for about 96% of the decrease, as foreign sales to Baxter dropped from
$1,496,000 in 1Q 1996 to $114,000 in 1Q 1997. Critical care products
represented 84% of international sales in 1Q 1997 compared to 92% in 1Q 1996.
UM believes it has substantial sales potential for its products in
international markets, and therefore plans to continue to commit resources to
international business expansion.
c) Gross Profit
Gross margins (profit after subtracting costs of manufacturing products from
revenues) in 1Q 1997, were 52.3% compared to 46.1% in 1Q 1996. The improvement
was achieved because of the percentage increase in sales of Ob/Gyn products from
41.9% of total sales in 1Q 1996 to 60.5% of sales in 1Q 1997, combined with a
sharp decrease in Baxter sales, which were among the Company's least profitable.
A primary short-term challenge for UM is absorption of manufacturing
overhead given the current sales volumes and depreciation related to recent
increases in fixed assets. To the extent UM is successful in growing obstetrics
and gynecology revenues, and in switching distribution channels from
distributors to direct representatives, the Company foresees continued gross
margin improvements.
d) Income from Operations
Operating profit, or income from operations, is the profit achieved after
subtracting operating expenses from gross profit. Operating expenses are
subdivided into sales, general and administrative (SG&A) expenses and research
and development (R&D) expenses. UM further divides SG&A into the two categories
of sales and marketing (S&M) expenses and general and administrative (G&A)
expenses.
As a percentage of sales, operating expenses increased to 31.2% in 1Q 1997
compared to 18.1% in 1Q 1996, despite a decrease of $192,000 in operating
expense dollars. First quarter 1997 selling, general and administrative (SG&A)
expenses decreased 5% from the amounts spent in 1996, but, as a percentage of
sales, increased to 26.6% of sales in 1Q 1997 from 14.5% of sales in 1996.
S&M expenses pertain primarily to the "direct sales" portion of UM's
business. In 1997, the S&M expense ratio is expected to remain above historical
levels for two reasons: 1) the decline in Baxter business will continue to
reduce total sales; and 2) the termination of two additional U.S. distributors
at the beginning of the year in favor of adding directly employed sales
representatives will increase incremental sales expenses.
R&D expenses in 1Q 1997 were 4.6% of sales compared to 3.6% of sales in 1Q
1996. Many R&D expenses are external costs relating to both process and product
validations, which costs can vary from period to period. Evidence that R&D
efforts over the recent past have been productive is becoming apparent, as UM
has launched the following six significant new products: Epitome, Liberty,
Cordguard(R), Lumin, FiltresseO, and Deltran IVO. The Company employs
specialist R&D resources not only to internally develop its own new product
ideas, but also, through joint development agreements, licensing of technology,
acquisitions and other arrangements, to enhance and complete to
commercialization projects initiated by others. For example, UM recently
announced a joint development project with Phillips Plastics Corporation and
Patton Biomedical Corporation to complete development and validation of a unique
gynecological speculum, called the Patton Speculum, designed to couple superior
physician visualization at the cervix with improved patient comfort. A speculum
is a commonly used instrument in gynecologic diagnostic as well as therapeutic
procedures.
First quarter 1997 income from operations was $1,092,524 compared to
$2,787,838 in 1Q 1996. First quarter 1997 operating margins were 21.1% compared
to 28.0% for the same quarter in 1996.
e) Non-operating Income
Non-operating income includes primarily royalties from licensing UM's
technology to other companies, interest and capital gains from investing the
Company's cash, and gains or losses from the sale of assets. Non-operating
income decreased $571,000 to $528,000 in 1Q 1997 from $1,099,000 in 1Q 1996, due
principally to an extraordinary payment for the use of UM's pressure monitoring
technology in 1Q 1996. Royalties from other medical device companies continue
to make a substantial contribution to non-operating income. Lower cash balances
have resulted in decreased investment income in 1Q 1997 compared to 1Q 1996.
Non-operating income during the remainder of 1997 is expected to be slightly
lower than during the same period of 1996 due to lower cash balances generating
less investment income, while royalties are expected to be similar in magnitude
to the last three quarters of 1996.
f) Net Income and EPS
Despite sharply lower sales in 1Q 1997, UM's net income expressed as a
percentage of sales continues to rank in the top tier of all U.S. publicly-
traded companies at 20%, compared to 25% in 1Q 1996 and 20% for all of 1996.
After income taxes, 1Q 1997 net income was $1,039,985, compared to $2,483,535 in
1Q 1996. The effective income tax rate in 1Q 1997 was 35.8% compared to 36.1%
in 1Q 1996.
Earnings per share (EPS) is net income divided by the number of shares of
stock outstanding (fully-diluted to take effect for stock options awarded which
have exercise prices below the current market value). Fully diluted 1Q 1997 EPS
were down 51.8% to $.12 compared to $.25 in 1Q 1996. First quarter 1997 ending
weighted average number of common shares assuming full dilution (the number used
to calculate EPS) were 8,730,724 shares compared to 10,041,513 in 1Q 1996. The
dilution calculation added about 100,000 shares to weighted actual shares
outstanding in 1Q 1997, compared to about 255,000 for 1Q 1996, due to quarter
ending share prices of $11.375 in 1Q 1997 compared to $16.75 in 1Q 1997. Actual
outstanding common shares as of March 31, 1997 were 8,608,486.
g) Cash Flows
Cash and investments balances were $3.0 million at the end of 1Q 1997, a
decrease of $1.5 million from December 31, 1996. The decrease was due primarily
to the use of $2.3 million for share repurchases. Cash provided by operating
activities, including adjustments for depreciation and other non-cash operating
expenses, along with changes in working capital, totaled $1,355,478 in 1Q 1997,
from $4,832,224 in 1Q 1996. Apart from net income, which accounted for about
42% of the decrease, a relative decrease of $1.0 million in accrued expenses and
a relative increase of $837 thousand in inventories were responsible for a
major portion of the decline compared to 1Q 1996. As of March 31, 1997, net
accounts receivable balances were $2.6 million which equates to 45 days sales in
receivables (based on 1Q sales), compared to end-of-year accounts receivable of
$3.8 million which also equates to 45 days in receivables. Inventory balances
are $1,178,000 higher than at the end of 1996, with inventory turns now at 1.8
times based on 1Q cost of sales.
Cash of $521,000 was used for capital expenditures in property and
equipment, with an additional $214,000 used to purchase intangible assets.
Capital expenditures during 1Q 1997 were made, primarily, in the automation of
key assembly operations, in new product tooling and equipment, for Midvale
building improvements, and for final payments on the Ireland facility. Net
purchases and sales of investments provided $405,000 to 1Q 1997 cash.
First quarter 1997 financing activities used cash of $2,163,000 after
repurchases of shares are netted against sales of shares from option exercises,
compared to $959,000 in the same period of 1996. The Company repurchased its
own common stock during 1Q 1997 in the amount of $2,258,000, up from $1,119,000
used in 1Q 1996. To the end of 1Q 1997, UM had spent about $37.7 million in
repurchasing 3,706,000 of its common shares since November 1992. In 1Q 1997,
the Company received $95,000 from issuing stock (on exercise of employee
options), compared to $160,000 in 1Q 1996. The Company did not enter into any
long-term debt agreements during the first quarter of 1997, but opened a $10
million unsecured line of credit in early April 1997 (see below).
Management believes that current cash balances plus future income from
operations will provide the liquidity needed to finance internal growth plans.
In addition to the capital expenditures, UM plans to use cash during the
remainder of 1997 for selective infusions of technological, marketing or product
manufacturing rights to broaden the Company's product offerings and for
continued share repurchases when the price of the stock remains extremely
undervalued.
Other
On April 4, 1997, the Company signed a revolving promissory note with its
bank. Under the note, the Company may borrow up to $10,000,000 at a floating
interest rate tied to LIBOR or the Prime Rate at UM's election. Amounts
borrowed under the note are unsecured and are due March 25, 1999. At May 10,
1997, the Company had borrowed $1,000,000 under the note at a current rate of
7.13% per annum.
- ---------------------------------------------------------------------------
PART II - OTHER INFORMATION
- ---------------------------------------------------------------------------
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
a) Exhibits: None
SEC
Exhibit Reference
No. No. Title of Document
- ------- --------- -----------------
1 27 Financial data schedule
b) Reports on Form 8-K: None
SIGNATURES
Pursuant to the requirements of the Securities Exchanges Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
UTAH MEDICAL PRODUCTS, INC.
REGISTRANT
Date: 5/13/97 By: /s/ Kevin L. Cornwell
CEO and CFO
</TABLE>
WARNING: THE EDGAR SYSTEM ENCOUNTERED ERROR(S) WHILE PROCESSING THIS SCHEDULE.
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE BALANCE
SHEET AS OF MARCH 31, 1997, AND STATEMENTS OF OPERATIONS FOR THE YEAR ENDED
DECEMBER 31, 1996, AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH
FINANCIAL STATEMENTS.
</LEGEND>
<S>.............................................................<C>
<PERIOD-TYPE>...................................................3-MOS
<FISCAL-YEAR-END>...............................................DEC-31-1996
<PERIOD-START>..................................................JAN-01-1997
<PERIOD-END>....................................................MAR-31-1996
<CASH>..........................................................1,904,590
<SECURITIES>....................................................1,069,975
<RECEIVABLES>...................................................2,683,962
<ALLOWANCES>....................................................(83,195)
<INVENTORY>.....................................................5,928,591
<CURRENT-ASSETS>................................................13,581,499
<PP&E>..........................................................20,598,856
<DEPRECIATION>..................................................(7,299,988)
<TOTAL-ASSETS>..................................................27,683,718
<CURRENT-LIABILITIES>...........................................4,153,126
<BONDS>.........................................................0
<COMMON>........................................................0
...........................................0
.....................................................86,085
<OTHER-SE>......................................................22,914,495
<TOTAL-LIABILITY-AND-EQUITY>....................................27,683,718
<SALES>.........................................................5,173,394
<TOTAL-REVENUES>................................................5,173,394
<CGS>...........................................................2,465,794
<TOTAL-COSTS>...................................................1,615,076
<OTHER-EXPENSES>................................................(528,401)
<LOSS-PROVISION>................................................0
<INTEREST-EXPENSE>..............................................0
<INCOME-PRETAX>.................................................1,620,925
<INCOME-TAX>....................................................580,940
<INCOME-CONTINUING>.............................................1,039,985
<DISCONTINUED>..................................................0
<EXTRAORDINARY>.................................................0
<CHANGES>.......................................................0
<NET-INCOME>....................................................1,039,985
<EPS-PRIMARY>...................................................0.12
<EPS-DILUTED>...................................................0.12
</TABLE>
